A Bridging Trial Comparing Sugammadex (Org 25969) at Reappearance of T2 in Japanese and Caucasian Participants. Part A: Japanese Participants (P05956)

PHASE2CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

January 3, 2006

Primary Completion Date

September 22, 2006

Study Completion Date

December 18, 2006

Conditions
Anesthesia, General
Interventions
DRUG

sugammadex

"After induction of anesthesia an intubation dose of NMBA was administered IV: either 0.9 mg/kg rocuronium or 0.1 mg/kg vecuronium.~Maintenance doses of 0.1-0.2 mg/kg rocuronium IV or 0.02-0.04 mg/kg vecuronium IV could be administered if necessary.~At reappearance of T2 the randomized single dose of sugammadex (0.5 to 4 mg/kg) IV was administered."

DRUG

Placebo

"After induction of anesthesia an intubation dose of NMBA was administered IV: either 0.9 mg/kg rocuronium or 0.1 mg/kg vecuronium.~Maintenance doses of 0.1-0.2 mg/kg rocuronium IV or 0.02-0.04 mg/kg vecuronium IV could be administered if necessary.~At reappearance of T2 the randomized single dose of placebo IV was administered"

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00591409 - A Bridging Trial Comparing Sugammadex (Org 25969) at Reappearance of T2 in Japanese and Caucasian Participants. Part A: Japanese Participants (P05956) | Biotech Hunter | Biotech Hunter